Revolution Medicines has reached another regulatory milestone with RASONQUE™ (Daraxonrasib). The U.S. Food and Drug Administration (FDA) has granted RASONQUE, in combination with gemcitabine and nab-paclitaxel, Breakthrough Therapy designation for first-line treatment of metastatic pancreatic cancer.
Revolution Medicines remains part of the UMBRELLA Strategy.
FDA designation shifts focus to first-line treatment in pancreatic cancer
The new Breakthrough Therapy designation covers RASONQUE in combination with gemcitabine and nab-paclitaxel (GnP) in patients with metastatic ductal adenocarcinoma of the pancreas who have not previously received treatment for metastatic disease.
The designation is intended to facilitate—and potentially accelerate—the development and review of therapies for serious conditions when preliminary clinical data indicate a substantial improvement over existing treatment options.
Importantly, Breakthrough Therapy designation does not constitute approval of RASONQUE for first-line treatment.
For Revolution Medicines, this is already the third Breakthrough Therapy designation for RASONQUE and the fifth within the RAS(ON) inhibitor portfolio.
Analyst assessment
Analyst sentiment toward Revolution Medicines remains positive following FDA approval and subsequent clinical developments.
| Analyst Consensus | Current |
|---|---|
| Recommendation | BUY |
| Number of Analysts | 21 |
| Average price target | approx. USD 251 |
| Upside potential | approx. +22% |
| Highest price target | USD 320 |
| Lowest price target | USD 179 |
Morgan Stanley initiated coverage on September 10 with an Overweight rating and a price target of USD 255. Key factors cited were the RASONQUE approval, the potential for further indication expansions, and combination therapies.
After the FDA approval in August, UBS raised its price target to USD 265.
Technical picture: consolidation continues
Revolution Medicines – daily chart, as of September 15, 2026
The technical picture remains positive overall, even though short-term momentum has eased after the strong rally of recent months.
| Indicator | Assessment | Interpretation |
|---|---|---|
| RSI (14) | Negative | Around 50 – balanced momentum, neither overbought nor oversold |
| MACD | Negative | A bearish crossover and a negative histogram signal weaker short-term momentum |
| Bollinger Bands | Negative | After the recent rally, the price has moved back toward the middle band |
Following the prior breakout, the stock therefore remains in a consolidation phase.
What we are watching
The latest FDA designation strengthens RASONQUE’s fundamental development outlook. At the same time, expectations for Revolution Medicines are already elevated after the strong share-price performance and the first FDA approval.
The focus is therefore on RASONQUE’s further clinical development, potential progress in additional indications, and the evolution of short-term technical momentum.
UMBRELLA Strategy
Revolution Medicines remains an important position within the UMBRELLA Strategy.
The latest Breakthrough Therapy designation represents another constructive fundamental development.
The position continues to be monitored within the defined risk management framework of the UMBRELLA Strategy.
Our existing valuation analysis of Revolution Medicines remains unchanged. This update focuses on the latest regulatory development as well as changes in analyst expectations and the technical picture.
